Journal article
Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial
Abstract
BACKGROUND: Concizumab is an anti-tissue factor pathway inhibitor monoclonal antibody in development as a once-daily, subcutaneous prophylaxis for patients with haemophilia A or haemophilia B with or without inhibitors. We aimed to assess the efficacy and safety of concizumab in patients with haemophilia A or B without inhibitors. Here we report the results from the confirmatory analysis cutoff.
METHODS: This prospective, multicentre, …
Authors
Chowdary P; Angchaisuksiri P; Apte S; Astermark J; Benson G; Chan AKC; Jiménez Yuste V; Matsushita T; Høgh Nielsen AR; Sathar J
Journal
The Lancet Haematology, Vol. 11, No. 12, pp. e891–e904
Publisher
Elsevier
Publication Date
December 2024
DOI
10.1016/s2352-3026(24)00307-7
ISSN
2352-3026